Skip to Content
Merck
  • Design of Peptoid-peptide Macrocycles to Inhibit the β-catenin TCF Interaction in Prostate Cancer.

Design of Peptoid-peptide Macrocycles to Inhibit the β-catenin TCF Interaction in Prostate Cancer.

Nature communications (2018-10-26)
Jeffrey A Schneider, Timothy W Craven, Amanda C Kasper, Chi Yun, Michael Haugbro, Erica M Briggs, Vladimir Svetlov, Evgeny Nudler, Holger Knaut, Richard Bonneau, Michael J Garabedian, Kent Kirshenbaum, Susan K Logan
ABSTRACT

New chemical inhibitors of protein-protein interactions are needed to propel advances in molecular pharmacology. Peptoids are peptidomimetic oligomers with the capability to inhibit protein-protein interactions by mimicking protein secondary structure motifs. Here we report the in silico design of a macrocycle primarily composed of peptoid subunits that targets the β-catenin:TCF interaction. The β-catenin:TCF interaction plays a critical role in the Wnt signaling pathway which is over-activated in multiple cancers, including prostate cancer. Using the Rosetta suite of protein design algorithms, we evaluate how different macrocycle structures can bind a pocket on β-catenin that associates with TCF. The in silico designed macrocycles are screened in vitro using luciferase reporters to identify promising compounds. The most active macrocycle inhibits both Wnt and AR-signaling in prostate cancer cell lines, and markedly diminishes their proliferation. In vivo potential is demonstrated through a zebrafish model, in which Wnt signaling is potently inhibited.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
3,5-Dimethoxyaniline, 98%
Sigma-Aldrich
2-phenoxyphenethylamine, AldrichCPR